ChemBioChem · 2016 · 38 citations · 25 references
PharmacyBiochemistryMedicinal ChemistryDrug DesignDrug DiscoveryProtein EngineeringPeptide Drug DiscoveryProtein DesignProtein SynthesisProteolytic EnzymesProteolytic ProcessingCyclic PeptidesMrna DisplayMrna Display Library ConstructionPeptide Display TechnologiesPeptide SelectionProtease ResistanceTumor-targeting PeptidesUnnatural Amino Acid Incorporation
Peptides typically have poor biostabilities, and natural sequences cannot easily be converted into drug-like molecules without extensive medicinal chemistry. We have adapted mRNA display to drive the evolution of highly stable cyclic peptides while preserving target affinity. To do this, we incorporated an unnatural amino acid in an mRNA display library that was subjected to proteolysis prior to selection for function. The resulting "SUPR (scanning unnatural protease resistant) peptide" showed ≈500-fold improvement in serum stability (t1/2 =160 h) and up to 3700-fold improvement in protease resistance versus the parent sequence. We extended this approach by carrying out SUPR peptide selections against Her2-positive cells in culture. The resulting SUPR4 peptide showed low-nanomolar affinity toward Her2, excellent specificity, and selective tumor uptake in vivo. These results argue that this is a general method to design potent and stable peptides for in vivo imaging and therapy.
25
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
Hyun‐Soo Cho, Karen Mason, Kasra X. Ramyar et al. · Nature · 2003 · 1.6K citations
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
Matthew C. Franklin, Kendall D. Carey, F.F. Vajdos et al. · Cancer Cell · 2004 · 1.1K citations · Full text